<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum>http://feeds2.feedburner.com/AmericanBankingNews</forum>
<forum_title>American Banking News</forum_title>
<discussion_title>Credit Suisse Reiterates Buy Rating for Agios Pharmaceuticals Inc (AGIO)</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://www.americanbankingnews.com/2016/04/25/credit-suisse-reiterates-buy-rating-for-agios-pharmaceuticals-inc-agio/</topic_url>
<topic_text>
Tweet 
Agios Pharmaceuticals Inc (NASDAQ:AGIO) ‘s stock had its “buy” rating reissued by equities researchers at Credit Suisse in a report released on Monday, Market Beat.com reports. 
In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 2,504 shares of the firm’s stock in a transaction dated Friday, February 26th. The shares were sold at an average price of $37.90, for a total value of $94,901.60. Following the completion of the sale, the director now owns 131,086 shares in the company, valued at approximately $4,968,159.40. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink . 
Shares of Agios Pharmaceuticals ( NASDAQ:AGIO ) traded up 2.55% during trading on Monday, hitting $55.93. The company had a trading volume of 474,658 shares. Agios Pharmaceuticals has a 52-week low of $33.50 and a 52-week high of $126.35. The firm’s market capitalization is $2.11 billion. The stock’s 50-day moving average is $43.11 and its 200 day moving average is $53.26. 
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, February 18th. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by $0.58. During the same period in the previous year, the company posted ($0.76) earnings per share. The company had revenue of $6.22 million for the quarter, compared to analyst estimates of $28.78 million. Equities research analysts predict that Agios Pharmaceuticals will post ($3.82) earnings per share for the current fiscal year. 
A number of other brokerages also recently weighed in on AGIO. Zacks Investment Research downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 5th. Janney Montgomery Scott began coverage on shares of Agios Pharmaceuticals in a research note on Tuesday, March 1st. They set a “neutral” rating and a $43.00 target price for the company. Canaccord Genuity reissued a “hold” rating and set a $50.00 target price (down from $70.00) on shares of Agios Pharmaceuticals in a research note on Friday, March 4th. JPMorgan Chase &amp; Co. reissued a “hold” rating on shares of Agios Pharmaceuticals in a research note on Thursday, March 31st. Finally, Goldman Sachs reduced their target price on shares of Agios Pharmaceuticals from $72.00 to $47.00 in a research note on Monday, February 22nd. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $80.04. 
A number of large investors recently bought and sold shares of AGIO. Capital World Investors boosted its stake in Agios Pharmaceuticals by 3.5% in the fourth quarter. Capital World Investors now owns 3,136,120 shares of the biopharmaceutical company’s stock valued at $203,597,000 after buying an additional 105,000 shares during the last quarter. BB Biotech AG boosted its stake in Agios Pharmaceuticals by 2.4% in the fourth quarter. BB Biotech AG now owns 2,159,921 shares of the biopharmaceutical company’s stock valued at $140,222,000 after buying an additional 50,000 shares during the last quarter. Clearbridge Investments LLC boosted its stake in Agios Pharmaceuticals by 317.6% in the fourth quarter. Clearbridge Investments LLC now owns 1,315,060 shares of the biopharmaceutical company’s stock valued at $85,374,000 after buying an additional 1,000,182 shares during the last quarter. Columbia Wanger Asset Management LLC boosted its stake in Agios Pharmaceuticals by 11.4% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 436,994 shares of the biopharmaceutical company’s stock valued at $28,370,000 after buying an additional 44,861 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in Agios Pharmaceuticals by 170.6% in the fourth quarter. Jennison Associates LLC now owns 430,085 shares of the biopharmaceutical company’s stock valued at $27,921,000 after buying an additional 271,142 shares during the last quarter. 
Agios Pharmaceuticals, Inc ( NASDAQ:AGIO ) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform.  //www.americanbankingnews.com/2016/04/25/credit-suisse-reiterates-buy-rating-for-agios-pharmaceuticals-inc-agio/   Agios Pharmaceuticals Inc   Agios Pharmaceuticals Inc  
</topic_text>
<spam_score>0.00</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://www.americanbankingnews.com/2016/04/25/credit-suisse-reiterates-buy-rating-for-agios-pharmaceuticals-inc-agio/</post_url>
<post_date>20160425</post_date>
<post_time>1840</post_time>
<username>ABMN Staff</username>
<post>
Tweet 
Agios Pharmaceuticals Inc (NASDAQ:AGIO) ‘s stock had its “buy” rating reissued by equities researchers at Credit Suisse in a report released on Monday, Market Beat.com reports. 
In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 2,504 shares of the firm’s stock in a transaction dated Friday, February 26th. The shares were sold at an average price of $37.90, for a total value of $94,901.60. Following the completion of the sale, the director now owns 131,086 shares in the company, valued at approximately $4,968,159.40. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink . 
Shares of Agios Pharmaceuticals ( NASDAQ:AGIO ) traded up 2.55% during trading on Monday, hitting $55.93. The company had a trading volume of 474,658 shares. Agios Pharmaceuticals has a 52-week low of $33.50 and a 52-week high of $126.35. The firm’s market capitalization is $2.11 billion. The stock’s 50-day moving average is $43.11 and its 200 day moving average is $53.26. 
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, February 18th. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by $0.58. During the same period in the previous year, the company posted ($0.76) earnings per share. The company had revenue of $6.22 million for the quarter, compared to analyst estimates of $28.78 million. Equities research analysts predict that Agios Pharmaceuticals will post ($3.82) earnings per share for the current fiscal year. 
A number of other brokerages also recently weighed in on AGIO. Zacks Investment Research downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 5th. Janney Montgomery Scott began coverage on shares of Agios Pharmaceuticals in a research note on Tuesday, March 1st. They set a “neutral” rating and a $43.00 target price for the company. Canaccord Genuity reissued a “hold” rating and set a $50.00 target price (down from $70.00) on shares of Agios Pharmaceuticals in a research note on Friday, March 4th. JPMorgan Chase &amp; Co. reissued a “hold” rating on shares of Agios Pharmaceuticals in a research note on Thursday, March 31st. Finally, Goldman Sachs reduced their target price on shares of Agios Pharmaceuticals from $72.00 to $47.00 in a research note on Monday, February 22nd. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $80.04. 
A number of large investors recently bought and sold shares of AGIO. Capital World Investors boosted its stake in Agios Pharmaceuticals by 3.5% in the fourth quarter. Capital World Investors now owns 3,136,120 shares of the biopharmaceutical company’s stock valued at $203,597,000 after buying an additional 105,000 shares during the last quarter. BB Biotech AG boosted its stake in Agios Pharmaceuticals by 2.4% in the fourth quarter. BB Biotech AG now owns 2,159,921 shares of the biopharmaceutical company’s stock valued at $140,222,000 after buying an additional 50,000 shares during the last quarter. Clearbridge Investments LLC boosted its stake in Agios Pharmaceuticals by 317.6% in the fourth quarter. Clearbridge Investments LLC now owns 1,315,060 shares of the biopharmaceutical company’s stock valued at $85,374,000 after buying an additional 1,000,182 shares during the last quarter. Columbia Wanger Asset Management LLC boosted its stake in Agios Pharmaceuticals by 11.4% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 436,994 shares of the biopharmaceutical company’s stock valued at $28,370,000 after buying an additional 44,861 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in Agios Pharmaceuticals by 170.6% in the fourth quarter. Jennison Associates LLC now owns 430,085 shares of the biopharmaceutical company’s stock valued at $27,921,000 after buying an additional 271,142 shares during the last quarter. 
Agios Pharmaceuticals, Inc ( NASDAQ:AGIO ) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform.  //www.americanbankingnews.com/2016/04/25/credit-suisse-reiterates-buy-rating-for-agios-pharmaceuticals-inc-agio/   Agios Pharmaceuticals Inc   Agios Pharmaceuticals Inc  
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>US</country>
<main_image>http://www.americanbankingnews.com/logos/agios-pharmaceuticals-inc-logo.jpg</main_image>
</document>
